COVID-19 & CancerFree Remdesivir, IL inhibitors emerge as frontrunners in race to treat COVID-19Phase III results for remdesivir expected within weeks April 24, 2020Vol.46 No.17By Matthew Bin Han Ong
Conversation with The Cancer LetterCOVID-19 & CancerFree As COVID-19 peaks in San Antonio, Ruben Mesa predicts gradual reopening April 22, 2020Vol.46 No.17By Paul Goldberg
FreeIn Brief J. Alan Diehl named deputy director and chief operating officer of Case CCC April 17, 2020Vol.46 No.16
FreeIn Brief Esther Welkowsky named VP, clinical operations, at Elicio Therapeutics April 17, 2020Vol.46 No.16
Drugs & TargetsFree FDA approves mitomycin for low-grade upper tract urothelial cancer April 17, 2020Vol.46 No.16
Drugs & TargetsFree Ontruzant, biosimilar of Herceptin, introduced in the U.S. April 17, 2020Vol.46 No.16
Clinical RoundupFree Elicio Therapeutics and NCI study ELI-002 mutant KRAS targeting mechanism April 17, 2020Vol.46 No.16
Clinical RoundupFree ACS study: JUUL sales bounced back within weeks of self-imposed flavor ban April 17, 2020Vol.46 No.16
